Biotest AG
Biotest AG (BIESF) Revenue
Annual & quarterly revenue history · segment & region breakdown
BIESF · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBiotest AG trailing twelve-month (TTM) revenue is $0.64B, an increase of 6.08% year-over-year from $0.73B in FY2024.
Revenue trend
2024 – 2005 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2024-12-31 | $0.73B | +$0.04B | +6.08% |
| 2023-12-31 | $0.68B | +$0.17B | +32.65% |
| 2022-12-31 | $0.52B | +$0.00B | +0.10% |
| 2021-12-31 | $0.52B | +$0.03B | +6.48% |
| 2020-12-31 | $0.48B | +$0.07B | +15.53% |
| 2019-12-31 | $0.42B | +$0.02B | +4.70% |
| 2018-12-31 | $0.40B | +$0.02B | +5.87% |
| 2017-12-31 | $0.38B | -$0.17B | -31.64% |
| 2016-12-31 | $0.55B | -$0.04B | -6.19% |
| 2015-12-31 | $0.59B | +$0.01B | +1.31% |
Compare revenue vs peers
BiotechnologyCompare BIESF revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Biotest AG receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Biotest AG reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in EUR.
Data sourced from Biotest AG's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
BIESF revenue · 4 questionsBIESF's trailing twelve-month (TTM) revenue is $0.64B. That is an increase of 6.08% year-over-year from $0.73B in FY2024.
▸ Source: FMP · Biotest AG SEC filings · GAAP · Biotest AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026